Røssevold et al. identify a subset of patients with early-stage basal-like breast cancer with an excellent prognosis, defined by high tumor expression of the immune checkpoint gene CTLA4. These patients are currently considered high-risk and receive extensive systemic treatment, which the authors suggest could safely be de-escalated or omitted.
- Andreas Hagen Røssevold
- Xavier Tekpli
- Jon Amund Kyte
